Financials

	2024	2025
Net sales	4.05Cr 4.67Cr 3.82Cr 3.47Cr 6.5Cr 447.85Cr 6.55Cr 46Cr 18Cr 227.19Cr 18Cr 17Cr 722.28Cr	4.11Cr 4.74Cr 3.88Cr 3.52Cr 6.6Cr 454.61Cr 6.65Cr 46Cr 18Cr 230.62Cr 18Cr 17Cr 733.18Cr
Net income	71.55L 82.57L 67.52L 61.25L 1.15Cr 79Cr 1.16Cr 8.06Cr 3.11Cr 40Cr 3.1Cr 3.03Cr 127.63Cr	47.82L 55.19L 45.13L 40.94L 76.81L 53Cr 77.36L 5.39Cr 2.08Cr 27Cr 2.07Cr 2.03Cr 85Cr
Net Debt	-1.73Cr -1.99Cr -1.63Cr -1.48Cr -2.77Cr -190.84Cr -2.79Cr -19Cr -7.49Cr -97Cr -7.48Cr -7.31Cr -307.78Cr	-2.1Cr -2.43Cr -1.99Cr -1.8Cr -3.38Cr -232.67Cr -3.4Cr -24Cr -9.14Cr -118.03Cr -9.12Cr -8.92Cr -375.25Cr

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

25/08	Lotus Bakeries, the most expensive speculoos on the (stock) market in Europe
30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	9.18Cr 11Cr 8.66Cr 7.86Cr 15Cr 1.02TCr 15Cr 103.46Cr 40Cr 515.13Cr 40Cr 39Cr 1.64TCr	P/E 2024 *	-	P/E 2025	-
Enterprise Value	7.08Cr 8.17Cr 6.68Cr 6.06Cr 11Cr 782.76Cr 11Cr 80Cr 31Cr 397.09Cr 31Cr 30Cr 1.26TCr	EV / Sales 2024	2.02x	EV / Sales 2025	1.67x
Free-Float	4.22%	Yield 2024 *	-	Yield 2025	-

25/08	Lotus Bakeries, the most expensive speculoos on the (stock) market in Europe
30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/23/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/22/30	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
12/22/12	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Global markets live: Daimler, GSK, Mattel
23/20/23	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/20/24	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
30/18/30	Eurofins Cerep SA acquired KVI-Plusz.	CI

18/25/18	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
13/23/13	Eurofins Cerep : annonce ses résultats 2022	PU

26/08	Lotus Bakeries, de duurste speculoos op de Europese beurs
26/08	Lotus Bakeries, la galleta más cara de la bolsa europea
25/08	Lotus Bakeries: Der teuerste Spekulatius der europäischen Börse
25/08	Lotus Bakeries, le spéculoos le plus cher de la bourse européenne
10/04	Eurofins Cerep : annonce ses résultats 2025

Director	Title	Age	Since
Paul Ratcliffe CHM	Chairman	-	11/08/2023
Damien Vielliard BRD	Director/Board Member	-	23/05/2024
Rodolphe Simonot BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.56%	-4.71%	-2.38%	+9.18%	4.55TCr
REVOLUTION MEDICINES, INC.	+0.98%	-0.75%	+345.38%	+532.15%	4.37TCr
IQVIA HOLDINGS INC.	+1.28%	+2.16%	+42.39%	+24.34%	4.31TCr
BEONE MEDICINES AG	+2.08%	+0.60%	+6.41%	+78.13%	3.94TCr
CELLTRION, INC.	+0.34%	-4.94%	+9.34%	+40.23%	3.19TCr
ASCENDIS PHARMA A/S	-0.55%	-2.72%	-	-	1.73TCr
MEDPACE HOLDINGS, INC.	+0.85%	+0.05%	+19.09%	+111.11%	1.64TCr
EUROFINS SCIENTIFIC SE	+2.07%	+0.78%	+14.39%	+30.91%	1.42TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.61%	-4.01%	+77.02%	+29.71%	1.33TCr
Average	+0.63%	-2.97%	+63.96%	+106.97%	2.94TCr
Weighted average by Cap.	+0.91%	-3.26%	+76.35%	+128.20%

End-of-day quote Euronext Paris
- ^EUR	-